Obsidan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Obsidan

Property Description
Active ingredient Propranolol hydrochloride
Form Oral tablets, Extended-release capsules, Injection
Pharmacological class Beta-Adrenergic Receptor Blocking Agent (Beta-blocker)
General purpose Cardiovascular support and modulation
Origin Synthetic

Obsidan is a well-established brand name for the pharmaceutical product containing the active chemical substance Propranolol (Propranolol hydrochloride). It is fundamentally classified as a Beta-Adrenergic Receptor Blocking Agent, commonly known as a beta-blocker. This compound is a synthetic, single-ingredient, prescription-only medication. Its core identity is that of a nonselective antagonist, meaning it modulates the effects of stimulating hormones like Adrenaline (Epinephrine) and Noradrenaline (Norepinephrine). This mechanism is utilized in clinical conditions sensitive to sympathetic nervous system activity.

Classification: Why Obsidan is a Nonselective Beta-Blocker

Obsidan belongs to the specific subclass of beta-blockers that are nonselective, meaning the substance blocks both the beta-1 (beta1) and beta-2 (beta2) adrenergic receptors located throughout various bodily tissues. This dual-receptor blockade provides the basis for its fundamental physiological effects, which include slowing the heart rate (a negative chronotropic effect) and reducing heart strain by decreasing the force of myocardial contraction (a negative inotropic effect). This action contributes to its designation as a Class II antiarrhythmic agent, an identity associated with its role in stabilizing heart rhythm. The medication is used for conditions that benefit from decreased cardiac work and stabilization of heart rhythm.

Dosage Forms and General Purpose of Obsidan

Obsidan is produced in multiple pharmaceutical preparations, offering versatility for patient management, including standard oral tablets, long-acting extended-release capsules, and a sterile solution suitable for intravenous injection. The general therapeutic purpose of this medication is centered on supporting and optimizing cardiovascular function. By reducing the heart's overall workload and lessening the stimulating impact of stress hormones, Obsidan contributes to the modulation of blood pressure and helps maintain a more stable, balanced heart rhythm.

What side effects are possible with Obsidan?

Possible Side Effects and Safety Information

The official safety profile for Obsidan (propranolol hydrochloride) is based on classifications from government regulatory documents, detailing potential adverse reactions across various body systems and specific population constraints. Adverse reactions are grouped by frequency observed in clinical use and post-marketing experience.

Frequency-Classified Adverse Reactions

The most frequently documented adverse effects involve the cardiovascular, nervous, and gastrointestinal systems.

Classification Examples of Documented Effects
Common Bradycardia (slow heart rate), Fatigue, Cold extremities, Sleep disturbances, Gastrointestinal discomfort (Nausea, Diarrhea)
Uncommon Mental depression, Paresthesia (tingling sensation)
Rare Visual disturbances, Hallucinations, Psychoses, Thrombocytopenia, Hair loss

Serious Safety Constraints

Regulatory documents highlight the potential for serious adverse reactions and specific constraints on use. The medication is associated with a risk of worsening heart failure and heart block in certain patients. A critical safety pattern noted in the label is the risk of myocardial infarction or severe angina pectoris if the therapy is abruptly discontinued, particularly in those with pre-existing heart conditions.

Due to its nonselective properties, the medicine is contraindicated in individuals with bronchial asthma or severe Chronic Obstructive Pulmonary Disease (COPD) due to the risk of inducing bronchospasm. Additionally, the drug may mask the clinical signs of acute hypoglycemia in diabetic patients and the physical symptoms of hyperthyroidism.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Official regulatory documents describe that an overdose of Obsidan (propranolol) may present with serious manifestations due to its effects on the cardiovascular, metabolic, and central nervous systems. Documented overdose presentations include profound hypotension (low blood pressure), marked bradycardia (slow heartbeat), and hypoglycaemia (low blood sugar).

Central Nervous System (CNS) effects such as drowsiness, confusion, and convulsions (seizures) are also reported. Severe consequences leading to cardiogenic shock, coma, and cardiac arrest are documented in the regulatory profile. Hypoglycaemia is noted as a specific risk in overdose, particularly for the pediatric population and elderly patients.

Required Emergency Actions

Regulatory authorities state that individuals must seek emergency medical attention immediately if an overdose is suspected or if severe symptoms develop. Urgent medical assistance is specifically required for the onset of symptomatic bradycardia or severe hypotension. In situations involving collapse, seizures, trouble breathing, or inability to be awakened, emergency services must be contacted immediately.

Management involves general symptomatic and supportive measures, including maintaining a clear airway and continuous monitoring of vital signs. Hospital monitoring and specific procedures such as gastric lavage or the administration of reversal agents (e.g., glucagon) are documented components of overdose treatment.

Therapeutic Uses of Obsidan

What Obsidan Treats: Main Uses and Benefits

Obsidan is commonly applied across domains where additional symptomatic support is needed for conditions related to the heart and circulation. It is relevant for managing established conditions such as hypertension, cardiac arrhythmias, angina pectoris, essential tremor, and for prophylaxis against migraine headaches. It is commonly used to help with groups of symptoms that may appear suddenly or fluctuate, such as palpitations and a rapid or irregular pulse. This provides support that helps ease the overall symptom burden, particularly by reducing the heart's workload, and is applied in clinical settings that involve acute or unstable symptom patterns related to the heart and circulation.

The medication is applied across domains involving certain distressing symptoms, being particularly relevant for easing symptoms that interfere with daily comfort, such as the pain associated with angina pectoris (chest pain). Its use contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort. In neurological contexts, it is used for managing symptoms of increased neurological or muscular activity, such as familial tremor, which are symptoms that create noticeable physiological strain.

“The primary goal of therapy with this medication is to help ease the impact of symptoms on routine activities and support general well-being during symptomatic phases.”

Quick Fact: Relief for Episodic Discomfort Obsidan is commonly used in situations involving recurrent or episodic manifestations to help reduce the frequency and intensity of symptoms associated with conditions like migraine headaches.

Regulatory References

  1. NIH DailyMed Label for Propranolol

Eligibility and Restrictions for Use

Obsidan (Propranolol) eligibility is defined by official regulatory criteria that restrict its use based on existing health conditions and patient demographics.

Who Must Not Use Obsidan

Obsidan is contraindicated and must not be used by patients with specific severe heart conditions, including cardiogenic shock, sinus bradycardia, or second- or third-degree heart block (unless a pacemaker is present). It is also prohibited for patients with bronchial asthma or a history of bronchospasm, as well as those with uncontrolled heart failure or metabolic acidosis. Use is also contraindicated in patients prone to hypoglycemia after prolonged fasting.


Age and Organ Function Restrictions

The use of standard Obsidan tablets and capsules is primarily established for the adult population. The safety and effectiveness of these forms have not been established for general use in children. A specific oral solution formulation is indicated only for infants, with treatment restricted to the age range of 5 weeks to 5 months for a particular condition.

Conditional use and special caution are required for patients with hepatic impairment (liver issues) or renal impairment (kidney issues), as these conditions may necessitate adjustments to ensure safe use. For pregnancy, use is restricted to cases where the benefit outweighs the potential risk, and close monitoring of the newborn is required upon delivery.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

The interaction profile of Obsidan, which contains propranolol, is defined by pharmacokinetic and pharmacodynamic mechanisms as documented in regulatory labeling.

Pharmacodynamic and Contraindicated Interactions

Co-administration with Non-dihydropyridine Calcium Channel Blockers (Verapamil, Diltiazem) is associated with a severe risk of bradycardia and heart block due to additive cardiac depression. Combining Obsidan with other Beta-Adrenergic Blocking Agents is generally restricted for the same reason. Alpha-Blockers (e.g., Prazosin) increase the risk of first-dose hypotension. NSAIDs may antagonize the blood pressure-lowering effect of propranolol.

Pharmacokinetic and Timing Restrictions

Propranolol is a substrate for multiple CYP enzymes, including CYP2D6, CYP1A2, and CYP2C19. Co-administration with enzyme inhibitors (e.g., Fluoxetine, Cimetidine) formally increases propranolol plasma concentrations, while inducers (e.g., Rifampin, Phenytoin) formally decrease them. For patients taking Clonidine, regulatory labeling requires propranolol withdrawal several days before Clonidine is gradually stopped to prevent severe rebound hypertension. Furthermore, taking Obsidan with food increases its bioavailability, and consistency in administration relative to meals is required. Fasting or illness may increase the risk of hypoglycemia and mask its typical warning signs.

Mechanism of Action

Blockade of Beta-Adrenergic Receptors

Obsidan (propranolol) is a non-selective beta-adrenergic receptor antagonist, primarily functioning by competitively blocking beta-1 (beta1) and beta-2 (beta2) adrenergic receptors. This engagement with beta-receptors modifies early molecular steps by preventing the binding of endogenous catecholamines (like norepinephrine and epinephrine). This suppression of agonist binding regulates overactive sympathetic processes and inhibits signaling sequences that lead to downstream excitatory effects across multiple systems.


Modulation of Systemic Function

Blocking beta1 receptors in the heart reduces sympathetic stimulation, resulting in negative chronotropy (decreased heart rate) and negative inotropy (decreased force of contraction). These modifications of key cardiac pathways lower myocardial oxygen consumption. Additionally, beta2 receptor blockade in peripheral vasculature and inhibition of renin release from the kidneys contribute to an adjustment in systemic hemodynamics, including modulation of systemic vascular resistance and cardiac output. This alteration of function also extends to the central nervous system, decreasing sympathetic outflow and altering the functional state within targeted neurological pathways.

Dosage and Administration Information

The administration of Obsidan (Propranolol hydrochloride) involves specific parameters concerning its physical form and required frequency. The medicine is available for use via the oral route as Immediate-Release (IR) tablets, Extended-Release (ER) capsules, or an oral solution, and by the intravenous (IV) route for acute, controlled settings.

Oral therapy begins with a standardized starting dose, typically 40 mg to 80 mg daily, which is then gradually increased (titrated) over specified intervals, often 3 to 7 days, to reach an established maintenance dose. Frequency is dictated by the formulation: IR tablets require administration in divided doses two to four times daily, while ER capsules are formulated for once-daily use. Standard practice involves maintaining consistency of intake—taking the medication the same way each time, either with or without food.

Specific procedural rules govern the proper administration of the forms. The ER capsule must be swallowed whole and must not be crushed or chewed, as this alters the intended sustained release. For certain populations, such as older adults or those with hepatic/renal impairment, therapy is initiated with a lower, cautious dose. The overall treatment course mandates that therapy must not be stopped abruptly; instead, the dosage must be reduced gradually over a period of 7 to 14 days to complete the course safely. If a single dose of the oral form is missed, standard procedures involve skipping the missed dose and resuming the normal schedule, avoiding doubling the next dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Obsidan

Evidence for Use in Managing High Blood Pressure and Angina Pectoris

Obsidan was evaluated in studies for conditions including high blood pressure (Hypertension) and chest pain related to heart blood flow (Angina Pectoris). For high blood pressure, research has primarily involved Randomized Controlled Trials (RCTs) and large-scale Systematic Reviews over many years. These studies monitored outcomes related to changes in blood pressure and cardiovascular function. Researchers observed patterns related to the frequency of major heart-related events over the long term. These findings describe group patterns observed in the studies, and research does not determine whether an individual will respond similarly.

For stable angina pectoris, research has explored the medication in short-term RCTs, often using a crossover design. Studies examined outcomes related to physical discomfort and daily functioning, specifically measuring exercise tolerance and the frequency of chest pain episodes. Studies reported data showing patterns related to the frequency of these episodic changes in the observed populations. Comparative evidence against contemporary cardiac procedures is limited within the core research base due to the age of the original studies.


Evidence for Use in Cardiac Rhythm Control and Neurological Symptoms

Obsidan was evaluated in studies focused on stabilizing irregular heart rhythms (arrhythmias). These studies, which include specialized Electrophysiological Studies, monitored outcomes reflecting episodic or acute changes in heart rate and rhythm. Research has also been applied in studies examining patient-reported outcomes describing perceived discomfort. Study findings were observed to vary depending on the type of irregular heart rhythm being treated.

In neurological settings, Obsidan was studied for conditions like essential tremor and for the prevention of migraine headaches. For tremor, RCTs examined outcomes related to daily functioning and used rating scales to measure how symptoms change. For migraine prophylaxis, numerous controlled trials explored short-term symptom changes, focusing on outcomes related to the frequency and intensity of headache episodes. Individual responses were found to vary.


Current Research Gaps and Uncertainties

The evidence base, while extensive, highlights several areas where certainty remains low. Many of the pivotal cardiovascular trials are historic, meaning comparative evidence against the full range of modern drug therapies is limited. This means the results are specific to the conditions under which they were conducted. Furthermore, subgroup findings are uncertain or heterogeneous across studies, particularly when evaluating patients with multiple health issues. Long-term effects on the durability of symptomatic changes are not fully established for all indications.

Key Studies & References Propranolol - StatPearls - NCBI Bookshelf (for cardiovascular, migraine, and tremor indications)

Frequently Asked Questions (FAQ)

Common questions about Obsidan (FAQ)


Q: Is it common to experience sleepiness when first starting Obsidan?

A: Regulatory documents state that common side effects can include feelings of tiredness, weakness, or dizziness. While 'sleepiness' isn't specifically named, these effects are related to the central nervous system and are commonly reported in early treatment.


Q: Is Obsidan known to cause long-term effects on the liver or kidneys?

A: Official product information indicates that for individuals who already have existing liver or kidney impairment, the drug is removed more slowly from the body. The official protocol for this patient population specifies caution and potential dose adjustments. The regulatory labeling primarily focuses on the need for caution in patients with pre-existing impairment.


Q: What are the risks associated with taking Obsidan during pregnancy or while trying to conceive?

A: Official information indicates that use in pregnancy is restricted to cases where the benefit outweighs the potential risk. Studies have associated use with potential risks to the fetus and newborn, including slow heart rate (bradycardia) and low blood sugar (hypoglycemia) upon delivery. Official guidance states that close monitoring of the newborn is a necessary protocol if the medication is used during pregnancy.


Q: Is Obsidan an older medicine or a relatively new drug?

A: The active ingredient in Obsidan, Propranolol, is a well-established medication. According to official records, the active ingredient was first approved for general adult use in 1967.


Q: What are the documented withdrawal symptoms associated with stopping Obsidan?

A: Regulatory documents warn that stopping this therapy abruptly, particularly for individuals with pre-existing heart conditions, can lead to severe adverse reactions. Documented risks include the onset of severe chest pain, irregular heartbeat, and myocardial infarction (heart attack). Official labeling mandates that any reduction in use must be gradual due to this risk.


Q: How is Obsidan processed and eliminated from the body?

A: Official pharmacokinetic data indicates that Obsidan is cleared very efficiently by the liver. Its elimination rate is highly dependent on the blood flow to the liver, where it is broken down through metabolic processes before being excreted from the body.


Q: Is Obsidan available in a generic version?

A: Yes, the active ingredient, which is Propranolol hydrochloride, is widely available in generic form. This includes generic versions of the tablet, capsule, and oral solution formulations.


Q: What is the main difference between Obsidan and similar generic medications?

A: Obsidan is the brand name for the active chemical substance Propranolol. Generic medications contain the identical active ingredient in the same strength. Differences typically relate only to cost, the specific inactive ingredients used, and the physical design of specialized dosage forms.


Q: Is Obsidan considered a controlled substance by regulatory agencies?

A: No, the official regulatory scheduling information states that the medication is not classified as a controlled substance under federal schedules. It remains a prescription-only medication.


Q: What are the official signs that indicate Obsidan is working for its intended use?

A: Since conditions like high blood pressure are often asymptomatic, the effect may not be perceptible to the patient. Effectiveness is assessed by healthcare providers primarily through changes in heart rate and blood pressure, or a reduction in the frequency of the specific symptoms (e.g., chest pain, tremor) related to the condition being treated.


Q: Does Obsidan affect the user's weight (gain or loss)?

A: Official safety information lists weight gain as a potential side effect associated with the beta-blocker class of medications. Additionally, fast or unusual weight gain is specifically documented as a warning sign of worsening heart failure that warrants prompt medical evaluation.


Q: What are the official descriptions of an allergic reaction to Obsidan?

A: Official safety documents list hypersensitivity reactions as a potential adverse effect. Signs of an allergic reaction may include a skin rash, hives, swelling of the face, lips, tongue, or throat, or difficulty breathing.


Q: How long do temporary side effects of Obsidan typically last after starting treatment?

A: Official patient guidance indicates that common side effects are generally mild. Many of these temporary symptoms are expected to wear off naturally as the body adjusts to the medication over a short period of time.


Q: Does Obsidan interact with or change the effectiveness of common hormonal birth control pills?

A: Studies and interaction profiles indicate that some hormonal contraceptives, specifically those containing ethinyl estradiol, may increase the concentration of Obsidan in the bloodstream. This interaction is associated with greater decreases in both blood pressure and heart rate.


Q: Is it acceptable to drink alcohol in moderation while taking Obsidan?

A: Official guidance advises against concurrent alcohol consumption due to its additive depressor effect on blood pressure. This combination can significantly increase the risk of adverse symptoms, such as excessive dizziness, lightheadedness, or fainting.


Q: Can Obsidan be taken alongside commonly used supplements like Vitamin D or fish oil?

A: Interaction profiles indicate that co-administration with certain supplements, such as multivitamins containing minerals, may decrease the effectiveness of Obsidan. Because of this potential interaction, a protocol of separating administration times may be followed.


Q: Is Obsidan considered safe for use while breastfeeding?

A: According to official NIH data, studies show that only low levels of the drug are found in breast milk. Adverse effects in the breastfed infant are not expected, though official guidance states that monitoring the infant for signs of beta-blockade is generally followed.


Q: Does Obsidan affect a person's ability to drive or operate machinery?

A: Official warning labels describe the risk to coordination, reaction time, or judgment, and state that activities requiring concentration should be avoided until the drug's effect is known.


Q: What general actions should be taken if someone accidentally takes too much Obsidan?

A: Accidental overdose is a medical emergency. The official protocol for accidental overdose involves immediate professional emergency care, continuous monitoring of vital signs, airway protection, and specific treatments to counteract the drug's effect on the heart.


Q: What is the best time of day to take Obsidan, based on official recommendations?

A: Official drug information indicates that the extended-release capsule is typically recommended to be taken once daily at bedtime. For all formulations, maintaining consistency of intake—taking the medication the same way each day—is officially stated as necessary for consistent effect.


Q: Is there any specific diet that must be followed while taking Obsidan?

A: Official labeling describes the drug as part of a complete program for chronic conditions, which often includes specific diet, exercise, and weight control routines.


Q: Is Obsidan approved for use as a long-term maintenance treatment?

A: Studies and official information indicate that the medication is approved for the management of chronic conditions such as high blood pressure and angina pectoris. These conditions typically require long-term maintenance treatment for control and support.


Q: How quickly does Obsidan usually start to work after the first dose?

A: Clinical data indicates that for high blood pressure, a significant effect on heart rate and blood pressure may be observed after the first dose. The near-maximum effect is typically achieved within 48 to 72 hours of continued therapy.


Q: Does Obsidan have a risk of misuse or dependency?

A: The drug is not scheduled as a controlled substance. However, isolated clinical reports have noted potential for misuse in specific anxiety-prone patient populations. Furthermore, abrupt cessation can cause severe rebound symptoms, and official labeling mandates gradual reduction due to this risk.


Q: Are there different brand names for the medicine Obsidan?

A: Yes, Obsidan is a brand name for the active chemical substance Propranolol. Other common brand names for this medication include Inderal LA, Innopran XL, and Hemangeol.

How should Obsidan be stored and disposed of?

How to Store and Dispose of Obsidan?

Obsidan (propranolol hydrochloride) must be stored under specific environmental constraints to maintain product stability and safety. The medication should be kept at Controlled Room Temperature, ideally between 20 C and 25 C.

Storage Requirements

  • Protection: The product must be protected from light, excess heat, and moisture. It should not be stored in high-humidity areas, such as a bathroom.
  • Container: Keep the medicine in its original container and ensure the lid is tightly closed.
  • Child Safety: It is mandatory to keep Obsidan out of the reach and sight of children.
  • Liquid Forms: Propranolol oral solution must be discarded within 60 days after the bottle is first opened, as stability is limited.

Disposal Instructions

Unused or expired Obsidan must be disposed of in accordance with local regulatory requirements to ensure environmental protection. The medicine should not be flushed down the toilet or poured down a sink unless specifically directed by official guidance. Utilizing a drug take-back program is the preferred disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Obsidan found in:

A-Z Index: